Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares. The company’s below-consensus FY25 weighed on the stock despite the modest Q4 revenue beat, but the organic revenue outlook embeds some conservatism, and several product launches by Zimmer should help drive a second-half-weighted revenue growth and EPS ramp, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $112 from $118 at Barclays
- Zimmer Biomet’s Strategic Growth Amid Challenges
- Zimmer Biomet price target lowered to $107 from $115 at Deutsche Bank
- Zimmer Biomet price target lowered to $125 from $130 at RBC Capital
- Zimmer Biomet price target lowered to $119 from $126 at Raymond James